Why Do Bisphosphonates Cause Osteonecrosis of the Jaw?

Bisphosphonates cause osteonecrosis of the jaw through a collision of several mechanisms: they suppress the bone-remodeling cells the jaw depends on more than almost any other bone, they reduce local blood supply, and they impair the soft tissue lining that normally seals jawbone off from the bacteria-rich mouth. No single mechanism fully explains it, which is part of why it took until 2003 for clinicians to recognize the condition despite bisphosphonates being used for decades. The jaw turns out to be uniquely vulnerable in ways that other skeletal sites are not, and the story involves everything from molecular signaling inside bone cells to the mechanics of chewing.

How Bisphosphonates Shut Down Bone Remodeling

Bone is not a static structure. It constantly breaks itself down and rebuilds, a process called remodeling. Osteoclasts dissolve old bone; osteoblasts lay down new bone in its place. Bisphosphonates work by targeting osteoclasts. The nitrogen-containing bisphosphonates, which include the most widely prescribed versions like alendronate, risedronate, and zoledronic acid, block a key enzyme pathway inside osteoclasts. This prevents the cells from modifying certain signaling proteins they need to function and survive, ultimately pushing the osteoclasts toward cell death.

That is exactly the therapeutic point. In osteoporosis or cancer that has spread to bone, osteoclasts are too active, dissolving bone faster than it can be replaced. Shutting them down slows bone loss and strengthens the skeleton. But the same suppression becomes a problem when bone needs to heal after an injury, an infection, or a dental procedure. Without functional osteoclasts to remove damaged bone and kick off the rebuilding cycle, necrotic (dead) bone accumulates and cannot be replaced. The jaw, it turns out, relies on this turnover cycle more heavily than most of the skeleton.

Why the Jaw Is Uniquely Vulnerable

The jawbone has the highest rate of bone turnover in the adult skeleton. Chewing generates constant mechanical stress, and the teeth create a direct interface between bone and the outside world. No other bone in the body is separated from an environment teeming with bacteria by just a thin layer of mucosa and a tooth socket. When bisphosphonates suppress remodeling throughout the skeleton, the jaw feels the consequences disproportionately because it had the most remodeling to lose.

Research on jawbone tissue from patients with bisphosphonate-related osteonecrosis has found molecular signatures consistent with this idea. Affected jaw specimens showed sharply reduced levels of osteopontin, a protein involved in bone turnover and blood vessel formation, alongside elevated levels of Dlx-5, a transcription factor linked to bone formation gone awry. The imbalance points to a localized disruption where the jaw’s normal repair signals are suppressed while abnormal bone-forming signals are amplified.

The thin mucosa overlying the jaw, particularly on bony prominences like the hard palate or the ridge where teeth sit, is another anatomic factor. This tissue can be easily traumatized by food, dental appliances, or even routine chewing. Once it breaks down and exposes the underlying bone, a chain of events begins that healthy bone would handle through remodeling but bisphosphonate-saturated bone cannot.

Reduced Blood Supply Compounds the Problem

Beyond suppressing osteoclasts, bisphosphonates also appear to interfere with the growth of new blood vessels. This anti-angiogenic effect has been studied most directly through VEGF, a protein the body uses to stimulate blood vessel formation. In patients who developed jaw osteonecrosis, serum VEGF levels were linked to the condition’s onset, providing evidence that the blood-vessel-suppressing properties of bisphosphonates play a direct role in how the disease develops.

This matters because healing from any bone injury requires a robust blood supply. New blood vessels deliver oxygen, immune cells, and growth factors to the injury site. When bisphosphonates dampen that process, the jaw loses two of its repair pathways simultaneously: osteoclast-driven bone remodeling and blood-vessel-driven tissue repair. The combination leaves injured jawbone in a kind of metabolic dead zone where damage accumulates but healing stalls.

The Soft Tissue Barrier Breaks Down

One underappreciated piece of the puzzle is that bisphosphonates do not just affect bone cells. They also impair the oral mucosa, the soft tissue lining the mouth. Laboratory studies have shown that bisphosphonate exposure inhibits the ability of oral mucosal cells to proliferate and close wounds, at concentrations similar to what patients actually experience during treatment. The cells did not die outright; they simply lost their capacity to migrate and fill in gaps.

⁴

This creates a vicious feedback loop. Oral surgery, a tooth extraction, or even a denture rubbing against the gum can break through the mucosal barrier. Normally, that tissue heals within days. In a patient on bisphosphonates, the wound closes more slowly or not at all, leaving underlying bone exposed to oral bacteria for an extended period. The exposed bone, already unable to remodel and repair itself, becomes a foothold for chronic infection.

What Actually Triggers the Exposed Bone

Most cases of bisphosphonate-related jaw osteonecrosis do not appear out of nowhere. They follow a triggering event. The strongest identified triggers are dental extractions and local infections. A large case-control study from a dental practice-based research network found that tooth extraction carried roughly a sevenfold increase in risk for osteonecrosis, while local infection with pus formation carried a similar or higher risk. Treatment duration also mattered: taking bisphosphonates for more than two years was independently associated with the condition.

⁵

Bacteria are not just bystanders once the bone is exposed. Actinomyces, a group of bacteria commonly found in the mouth, has been identified deep within the bone specimens of patients with osteonecrosis, not just on the surface. This finding argues that the bacteria are actively involved in the disease process, invading bone that can no longer defend or repair itself.

⁶

Even minor, non-surgical trauma can be enough. A reported case involved a patient whose prominent torus palatinus, a benign bony growth on the roof of the mouth, developed osteonecrosis after repeated contact with forks and spoons during eating. The mucosa covering such bony prominences is particularly thin and fragile, and once disrupted in a patient on bisphosphonates, the exposed bone became necrotic.

⁷

Why Dose, Route, and Indication Matter So Much

Not all bisphosphonate patients face the same risk. The distinction between intravenous (IV) and oral bisphosphonates, and between cancer and non-cancer indications, is enormous. A review of reported cases found that about 94% of osteonecrosis cases occurred in patients receiving IV bisphosphonates, with only about 6% in patients on oral formulations. The vast majority had cancer.

⁸

A study tracking over 25,000 patients who received IV zoledronic acid put numbers to this gap. Among cancer patients, the six-year probability of developing jaw osteonecrosis was about 0.6%. Among non-cancer patients receiving the same drug intravenously, it was 0.08%, roughly one-sixth the hazard even after accounting for the number of infusions.

⁹

The reason for the difference is partly pharmacologic: cancer patients receive much higher and more frequent doses. Zoledronic acid for bone metastases is typically given monthly at doses many times higher than the once-yearly infusion used for osteoporosis. But cancer patients also tend to be on other medications that compound the risk, including corticosteroids and chemotherapy agents that suppress immune function and further impair wound healing.

Bisphosphonates Stay in Bone for Years

A distinctive feature of bisphosphonates is their skeletal persistence. These molecules bind tightly to hydroxyapatite, the mineral crystal that gives bone its rigidity. Once embedded, they have an extremely long half-life, potentially lasting years, because they are released only when that particular segment of bone is broken down by osteoclasts.

¹⁰

This is a double-edged property. It means that a short course of treatment can produce lasting benefits for conditions with high bone turnover. But it also means that stopping the drug does not immediately remove its effect. Bisphosphonate molecules stored deep in bone are probably inactive, but significant amounts get released during the resorptive process. For a patient who develops osteonecrosis, simply discontinuing the medication does not clear the drug from the affected area for months or even years. This skeletal reservoir is why “drug holidays,” pausing bisphosphonate use before dental surgery, remain controversial in terms of how much protection they actually offer.

Genetic Susceptibility and Why Some Patients Are Hit Harder

Only a fraction of patients on bisphosphonates develop jaw osteonecrosis, which has prompted searches for genetic explanations. A genome-wide analysis of multiple myeloma patients treated with bisphosphonates identified variants in the CYP2C8 gene, part of the cytochrome P450 enzyme family involved in drug metabolism, that were associated with osteonecrosis risk. Patients carrying two copies of one particular variant allele had roughly a thirteenfold increased likelihood of developing the condition compared to those without it.

¹¹

Subsequent research confirmed that this CYP2C8 polymorphism was an independent marker for osteonecrosis risk in myeloma patients on bisphosphonates.

¹²

These findings are still limited to specific cancer populations and have not yet translated into routine genetic screening before prescribing bisphosphonates. But they reinforce the idea that individual biology, not just drug exposure, determines who gets osteonecrosis. Some patients may metabolize bisphosphonates differently, leading to higher local concentrations in bone or different patterns of drug release during remodeling.

Corticosteroids and Other Compounding Medications

Bisphosphonates are rarely used in isolation in cancer patients. Corticosteroids, commonly prescribed alongside chemotherapy for their anti-inflammatory and anti-nausea effects, appear to worsen the risk. Clinical observations have found that patients taking steroids along with bisphosphonates tend to develop osteonecrosis sooner, experience more severe disease, and respond more slowly when bisphosphonates are discontinued.

¹³

Steroids impair immune function and wound healing through their own mechanisms, compounding the soft tissue and bone repair problems that bisphosphonates already cause. Other medications that suppress blood vessel growth, such as certain targeted cancer therapies, add yet another layer of risk. The term “medication-related osteonecrosis of the jaw” (MRONJ) has largely replaced “bisphosphonate-related osteonecrosis” in recent clinical guidelines, partly to acknowledge that the condition can result from several drug classes, not bisphosphonates alone. Denosumab, a biologic drug that blocks a different molecular signal but achieves the same endpoint of suppressing osteoclast function, also carries MRONJ risk.

¹⁴

What Can Be Done Before Treatment Starts

The most effective intervention is prevention, and the evidence consistently points to dental screening before a patient ever starts bisphosphonate therapy. Multiple systematic reviews have emphasized that a thorough oral exam by a dentist should happen before treatment begins. Non-restorable teeth should be extracted, ill-fitting dentures adjusted, and active infections treated while the patient’s bone still has normal remodeling capacity.

¹⁵

Regular dental follow-ups, recommended at least every six months during treatment, help catch problems before they require invasive procedures. Patients should also be informed about the risk and encouraged to report any new oral symptoms early. Oral hygiene and mouth disinfection protocols are considered standard preventive measures, though the evidence for their effectiveness comes mostly from observational data rather than randomized trials.

Drug holidays, the practice of pausing bisphosphonates before dental surgery, remain a subject of debate. Current expert recommendations suggest that for patients who have been on oral bisphosphonates for osteoporosis for more than four years, or for a shorter period with additional risk factors, temporary discontinuation for roughly two months before and three months after an invasive dental procedure may be considered, in consultation with the prescribing physician. The supporting evidence for this strategy is limited, and the long skeletal half-life of bisphosphonates means the drug’s effects do not simply disappear during the pause.

¹⁶

Treatment When Osteonecrosis Develops

Once osteonecrosis of the jaw is established, management has traditionally been conservative: antibacterial mouth rinses, antibiotics for secondary infections, careful surgical removal of dead bone fragments when necessary, and pain control. These approaches manage symptoms but do not reliably reverse the underlying problem of bone that cannot remodel itself.

A more promising approach targets the remodeling deficit directly. Teriparatide, a form of parathyroid hormone that stimulates new bone formation, has been tested in a placebo-controlled randomized trial for MRONJ. After one year, about 45% of osteonecrosis lesions resolved in the teriparatide group compared with about 33% in the placebo group, and patients on teriparatide showed reduced bony defects.

¹⁷

The logic is straightforward: if bisphosphonates cause the problem by shutting down bone remodeling, a drug that restarts it should help. Earlier case series had already suggested that teriparatide improved bone markers and produced radiographic evidence of healing, though those studies lacked control groups.

¹⁸

Teriparatide does carry an important limitation: it is contraindicated in patients with active bone cancers or a history of bone radiation, which excludes many of the highest-risk patients. For cancer patients, treatment remains largely supportive, and the search for effective therapies continues.

How the Condition Was Recognized

Bisphosphonates were used for decades with what was considered a strong safety profile before the jaw connection was identified. The first reports of bisphosphonate-related osteonecrosis appeared in 2003.

¹⁹

The delay was partly because the condition was rare, particularly at the lower doses used for osteoporosis, and partly because jawbone necrosis was already a known complication of radiation therapy and certain infections. Clinicians initially attributed these cases to other causes. It was only after cancer centers began seeing clusters of jaw necrosis in myeloma and breast cancer patients receiving high-dose IV bisphosphonates that the pattern became unmistakable. The recognition reshaped prescribing practices, dental screening protocols, and the informed-consent process for patients starting these medications, particularly those with cancer diagnoses requiring aggressive dosing regimens.